Tesamorelin

What it is

Tesamorelin is a 44-amino acid synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary to release growth hormone. It is chemically modified with a trans-3-hexenoic acid group at its N-terminus, which stabilizes it against enzymatic degradation and extends its half-life compared to native GHRH. Like CJC-1295, it works by stimulating the pituitary's own GH production rather than introducing exogenous GH directly, which preserves natural feedback regulation.

The compound was developed by Theratechnologies and approved by the FDA in 2010 under the brand name Egrifta, making it one of the few GHRH analogs with a confirmed pharmaceutical indication. The approved use is narrow: reduction of excess visceral adipose tissue (VAT) in adults with HIV who have developed lipodystrophy, a redistribution of body fat that is a known side effect of certain antiretroviral therapies. A reformulated lower-volume version (Egrifta SV) was approved in 2021.

What researchers study it for

• Visceral adipose tissue reduction in HIV lipodystrophy The pivotal clinical trials demonstrated that daily subcutaneous tesamorelin reduced visceral adipose tissue by approximately 15 to 18% compared to placebo over 26 weeks, with improvements in trunk-to-limb fat ratio and patient-reported body image. Sustained reductions were maintained over 52 weeks with continued treatment. [1] A 2024 analysis confirmed efficacy and safety in people with HIV on integrase strand transfer inhibitor (INSTI) regimens, which are now the dominant antiretroviral class. [3]
• Hepatic steatosis and liver health in HIV Nonalcoholic fatty liver disease is more common and more aggressive in people with HIV than in the general population. A JCI Insight study found that tesamorelin treatment was associated with reductions in liver fat content and favorable changes in hepatic gene expression related to fibrosis and metabolic signaling pathways. [2] The 2026 meta-analysis confirmed improvements in hepatic fat alongside lean body mass and IGF-1 levels in HIV-associated lipodystrophy cohorts. [4]
• Cognitive function in growth hormone-deficient populations A randomized trial by Baker et al. examined whether GHRH administration could improve cognitive function in adults with mild cognitive impairment (MCI) and found improvements in executive function and verbal memory scores compared to placebo, with effects correlating with increases in IGF-1. [5] More recent work in people with HIV and abdominal obesity found that while tesamorelin reduced waist circumference, the cognitive benefits did not significantly differ between groups, underscoring that the cognitive signal remains preliminary. [3]
• Metabolic markers and lipid profiles Beyond fat redistribution, clinical trials have documented improvements in triglycerides and total cholesterol in treated individuals, consistent with the metabolic role of GH signaling in lipid metabolism. These effects are generally modest and secondary to the primary VAT endpoint in HIV lipodystrophy trials. [1]

Research context

Tesamorelin has the most robust human clinical evidence of any GHRH analog, by virtue of its FDA approval pathway. The pivotal trials are large, well-controlled, and peer-reviewed, which distinguishes it clearly from most peptides in this category. [1] That said, the approved indication is specific: HIV-associated lipodystrophy in adults. Evidence for tesamorelin in people without HIV, in general obesity, or in age-related somatopause is far thinner and largely derived from smaller or exploratory studies.

The cognitive research is intriguing but not yet conclusive. The Baker et al. GHRH-MCI trial was one of the first to test the hypothesis that restoring IGF-1 signaling through endogenous GH stimulation might slow cognitive decline. [5] The more recent HIV-population cognition trial returned a null result on the cognitive primary endpoint, though it may have been underpowered. Researchers interested in the GH axis and cognitive aging should treat this as an active area of inquiry rather than an established finding. Research-grade tesamorelin from peptide vendors is not subject to pharmaceutical manufacturing standards and is not equivalent to Egrifta.

Typical research parameters

References

1. [1] Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled, double-blind, randomized, placebo-controlled phase 3 trial with safety extension data. Journal of Clinical Endocrinology and Metabolism. 2010;95(9). PubMed ↗
2. [2] Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16). PubMed ↗
3. [3] Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12). PubMed ↗
4. [4] Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy. Obesity Research and Clinical Practice. 2026;20. PubMed ↗
5. [5] Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11). PubMed ↗

Related